{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/neuropathic-pain-drug-treatment/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"2e3e3fff-20af-56ab-b8f8-a9ee4f14f833","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field 2ad66f0e-ef8e-41a3-b492-35ff4e3fe347 --><h2>Update</h2><!-- end field 2ad66f0e-ef8e-41a3-b492-35ff4e3fe347 -->","summary":null,"htmlStringContent":"<!-- begin item 257d0cc8-bf6a-42b8-8e7d-1d7a3697762c --><!-- end item 257d0cc8-bf6a-42b8-8e7d-1d7a3697762c -->","topic":{"id":"b1f9c908-6cb6-5afd-a737-0a621c6232d0","topicId":"35e3d915-8243-4418-a7dd-6590d8ca5c85","topicName":"Neuropathic pain - drug treatment","slug":"neuropathic-pain-drug-treatment","lastRevised":"Last revised in December 2020","chapters":[{"id":"0c243e96-3697-5ee3-98c7-9ffecf07f2af","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"94d784c6-0537-5187-a548-a95e6ad2f899","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"855f03f8-54cb-5675-a6b8-aeb8064288d7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f0b9b63a-bd52-51b6-8eda-cb26c9f551a0","slug":"changes","fullItemName":"Changes"},{"id":"2e3e3fff-20af-56ab-b8f8-a9ee4f14f833","slug":"update","fullItemName":"Update"}]},{"id":"80218328-d006-5b34-a01a-0ef4dbeaf7d5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"22989c5e-df85-5aba-bd66-8c44723e59d7","slug":"goals","fullItemName":"Goals"},{"id":"722de221-9258-5985-8a02-c088cf258a12","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"bf3b0c22-2d82-5464-bf76-bc066dae256f","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c6576f2f-fd04-5900-a5e1-517233523e2c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"dd2de31a-79d5-5c20-9132-c99c41c12822","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"148cc621-37d8-5264-a358-c380fcfb4223","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"eddf36b3-7bc8-53c9-9c59-fa36b809f229","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"025ef443-81b5-565d-8240-d76615c27e55","slug":"definition","fullItemName":"Definition"},{"id":"3704349e-d3ae-5a8b-ba94-9da5282ed77f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e18339e8-95d0-582f-ad51-0614dae8f855","slug":"complications","fullItemName":"Complications"},{"id":"9b552f08-01aa-583d-900b-9cbdc90fe28d","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"21d7485a-b855-5ba4-82bc-ca3154184325","fullItemName":"Management","slug":"management","subChapters":[{"id":"bad22859-57ae-5c1c-a944-c3d9fef6d160","slug":"neuropathic-pain-drug-treatment","fullItemName":"Scenario: Neuropathic pain - drug treatment"}]},{"id":"0d8cb386-e038-5d6f-83af-81664da82cca","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a91a8f28-db46-58e8-9df7-f30be0f00f2b","slug":"amitriptyline","fullItemName":"Amitriptyline"},{"id":"382b9603-7b46-57d1-9b07-fa743886796e","slug":"pregabalin","fullItemName":"Pregabalin"},{"id":"498f1249-e619-5b41-b42b-1a914239d269","slug":"gabapentin","fullItemName":"Gabapentin"},{"id":"201a6fcc-11c6-5f00-b820-7fa69ee8b95d","slug":"duloxetine","fullItemName":"Duloxetine"},{"id":"56e4231d-ab93-5963-bc8a-989240189179","slug":"capsaicin-cream","fullItemName":"Capsaicin cream"},{"id":"01a263c7-9fe1-5a29-95ec-24e56c0c1bc9","slug":"tramadol","fullItemName":"Tramadol"}]},{"id":"9ed9a9fb-0b52-50ef-8980-c1303531094d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4fd6ab13-09e0-57f4-a265-464eeab8c835","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"3eb7f136-ffd0-5f27-b2d1-21b49247596d","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"606fc7bf-da44-5385-95f8-0139b3c57ef7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"9fc3997f-80c3-5333-b5bd-3b3a518bdde6","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"74708745-26ce-5fd4-8c02-67ba25b5a355","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4f5855b4-c905-54ca-b02a-820f8fdd4a4a","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f09723db-fe39-5bbd-b643-d063fcd61d42","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"855f03f8-54cb-5675-a6b8-aeb8064288d7","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"d0511ee6-5ba9-5a2a-a9be-f49e760e07c9","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field 260883de-88ce-4049-93a1-3269afbed3a2 --><h3>New evidence</h3><!-- end field 260883de-88ce-4049-93a1-3269afbed3a2 -->","summary":null,"htmlStringContent":"<!-- begin item 2972e8db-ae95-4102-8045-37d1d82c9d22 --><!-- begin field 32de3eb8-0516-4b2b-8ae2-4fabc1f314e9 --><h3>Evidence-based guidelines</h3><!-- end field 32de3eb8-0516-4b2b-8ae2-4fabc1f314e9 --><!-- begin field 4840cb5e-f931-4d3c-9bf1-d09d062a6ad7 --><ul><li>Mathieson, S., Lin, C-W., Underwood, M. et al. (2020) <em>Pregabalin and gabapentin for pain.</em> BMJ. <a href=\"https://www.bmj.com/\" data-hyperlink-id=\"4cc25e3d-5e32-4f48-bb42-abae00b41905\">www.bmj.com</a> [<a href=\"https://www.bmj.com/content/369/bmj.m1315\" data-hyperlink-id=\"cf22d063-7cd3-4b94-95d4-abae00b41916\">Abstract</a>] </li></ul><!-- end field 4840cb5e-f931-4d3c-9bf1-d09d062a6ad7 --><!-- begin field 98ef8480-eb2a-43bc-8586-05be952badd7 --><h3>HTAs (Health Technology Assessments)</h3><!-- end field 98ef8480-eb2a-43bc-8586-05be952badd7 --><!-- begin field bcdafb76-d3dd-4da0-8bcf-968717ae2891 --><p>No new HTAs since 1 February 2020.</p><!-- end field bcdafb76-d3dd-4da0-8bcf-968717ae2891 --><!-- begin field d121d378-f0ea-4bc1-8d8b-2a7ade22f05f --><h3>Economic appraisals</h3><!-- end field d121d378-f0ea-4bc1-8d8b-2a7ade22f05f --><!-- begin field 5dcf52f2-8520-47c2-bd75-10eff8e1f145 --><p>No new economic appraisals relevant to England since 1 February 2020.</p><!-- end field 5dcf52f2-8520-47c2-bd75-10eff8e1f145 --><!-- begin field d87c0540-7adc-417c-b146-1b3c198575df --><h3>Systematic reviews and meta-analyses</h3><!-- end field d87c0540-7adc-417c-b146-1b3c198575df --><!-- begin field bb86131d-d7dc-4621-8f33-3fd2e59789c5 --><p>No new systematic reviews published since 1 February 2020.</p><!-- end field bb86131d-d7dc-4621-8f33-3fd2e59789c5 --><!-- begin field 94d130dc-5e66-4437-9250-a26f5cd01855 --><h3>Primary evidence</h3><!-- end field 94d130dc-5e66-4437-9250-a26f5cd01855 --><!-- begin field 9f9d226c-d90e-4301-98ee-149c8299c295 --><p>No new randomized controlled trials published in the major journals since 1 February 2020.</p><!-- end field 9f9d226c-d90e-4301-98ee-149c8299c295 --><!-- end item 2972e8db-ae95-4102-8045-37d1d82c9d22 -->","subChapters":[]},{"id":"01b5e873-92d6-588b-a407-a8afd3b6d8d3","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field 8fff3f40-2a48-4733-87cf-6908da241369 --><h3>New policies</h3><!-- end field 8fff3f40-2a48-4733-87cf-6908da241369 -->","summary":null,"htmlStringContent":"<!-- begin item 6ed7257d-44fb-4c71-823c-a450540a15ba --><!-- begin field 66c2493c-aec3-425f-b75e-f29ecfedfc3f --><p>No new national policies or guidelines since 1 February 2020.</p><!-- end field 66c2493c-aec3-425f-b75e-f29ecfedfc3f --><!-- end item 6ed7257d-44fb-4c71-823c-a450540a15ba -->","subChapters":[]},{"id":"e1c545ee-3bf7-5888-8f1f-b8e0cf4380ba","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field c1ed1c05-c48a-483c-b445-69d7a8f836bd --><h3>New safety alerts</h3><!-- end field c1ed1c05-c48a-483c-b445-69d7a8f836bd -->","summary":null,"htmlStringContent":"<!-- begin item 355273be-675f-4310-a5e5-73c4e5ec5429 --><!-- begin field b3a555c5-5a25-4d5c-9fcd-4e8357418614 --><p>No new safety alerts since 1 February 2020.</p><!-- end field b3a555c5-5a25-4d5c-9fcd-4e8357418614 --><!-- end item 355273be-675f-4310-a5e5-73c4e5ec5429 -->","subChapters":[]},{"id":"982b655e-3e3d-5954-8ff5-1b6dc206fdbb","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field 5ec5ef08-3f41-442f-b8ff-d7caa73d610d --><h3>Changes in product availability</h3><!-- end field 5ec5ef08-3f41-442f-b8ff-d7caa73d610d -->","summary":null,"htmlStringContent":"<!-- begin item 654128f3-01f4-45e3-a899-8af3a4caddb0 --><!-- begin field fea7da33-7d61-434f-a22b-a51d26790828 --><p>No changes in product availability since 1 February 2020.</p><!-- end field fea7da33-7d61-434f-a22b-a51d26790828 --><!-- end item 654128f3-01f4-45e3-a899-8af3a4caddb0 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}